SequelSEC

Neuphoria Therapeutics Inc. NEUP

Pharmaceutical Preparations · CIK 0001191070 · Fiscal year ends 0630

Revenue
$1.17M
Fiscal year ended 2026-06-30
Operating income
-$16.45M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$7.02MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$1.30Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue6.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2026-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio27.85x98th
Revenue YoY growth-92.5%12th
Net margin-1145.7%30th
Operating margin-1401.1%30th
SBC / revenue29.9%54th

Neuphoria Therapeutics Inc. (NEUP) reported revenue of $1.17M and net income of -$13.45M for the fiscal year ended 2026-06-30. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Neuphoria Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Neuphoria Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Revenue$1.17M$15.65M
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$16.45M-$1.13M
Net income-$13.45M-$369.63K
Research & developmentUnavailable$9.01M
Weighted-average diluted sharesshares 4.40Mshares 1.62M
Pretax income-$13.59M-$838.00K
Income tax expense-$139.17K-$468.37K
Diluted EPS$-3.06$-0.23
Selling, general & administrativeUnavailableUnavailable
General & administrative$7.44M$7.77M
Selling & marketingUnavailableUnavailable

Balance

Neuphoria Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Cash & equivalents$19.87M$14.21M
Total assets$28.71M$28.59M
Current assets$21.07M$15.04M
Total liabilities$4.11M$9.59M
Current liabilities$756.58K$4.22M
Total equity incl. NCI$24.60M$19.00M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivable$813.43K$11.95K
Goodwill$3.50M$8.64M
Long-term debtUnavailableUnavailable
Accounts payable$385.58K$1.15M

Cash flow

Neuphoria Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Operating cash flow-$12.35M$77.23K
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailableUnavailable
Financing cash flow$17.92M$1.53M
Net change in cash$5.58M$1.60M
Stock-based compensation$351.60K$163.77K
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$662.96K$662.89K

Derived

Neuphoria Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating margin-1401.1%-7.2%
FCF marginUnavailableUnavailable
SBC / revenue29.9%1.0%
Current ratio27.85x3.56x
Revenue YoY growth-92.5%Unavailable
Net margin-1145.7%-2.4%
R&D / revenueUnavailableUnavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NEUP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-18View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.